Karl Beutner, DermBiont CEO
October 25, 2023 06:51 AM EDT
Financing

DermBiont rais­es $35.2M Se­ries B to ad­vance two der­ma­to­log­i­cal drugs through PhII

Katherine Lewin

News Reporter

Boston biotech DermBiont closed a $35.2 mil­lion fund­ing round Tues­day to ad­vance de­vel­op­ment of two of its der­ma­to­log­i­cal top­i­cal can­di­dates. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times